Clinical trials: mCRPC, active
Prostate Cancer (CRPC)
Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
The goal of this clinical trial is to learn if tinengotinib combined with darolutamide or enzalutamide works to treat participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior androgen…
- Trial name
- NCT07871110
- Testing
- tinengotinib 10 mg QD plus darolutamide, tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide, tinengotinib 10 mg QD plus enzalutamide
- Where
- 16 sites in China
- Volunteers
- 182 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Metastatic Castration-resistant Prostate Cancer
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open-label, phase 1b dose-escalation study of cabozantinib in combination with 177Lu-PSMA-617 in subjects with mCRPC.
- Trial name
- CaboLu (NCT05613894)
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Utah
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, dosimetry and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617)…
- Trial name
- NCT06004661
- Testing
- AAA617, 68Ga-PSMA-11
- Where
- 9 sites in United States, France and 3 more
- Volunteers
- 23 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC）
This study is a prospective, single-center, single-arm clinical trial consisting of two parts. In Part A, 3 participants were enrolled to receive sequential administrations of low doses of [177Lu]Lu-PSMA-137 and…
- Trial name
- NCT06546527
- Testing
- [177Lu]Lu-PSMA-137
- Volunteers
- 12 people
- Sponsor
- Peking University First Hospital
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
This study will determine the safe initial injected activity of the radioligand therapy 177Lu-HTK03170 for the measurement of dosimetry and initiation of treatment in subjects with PSMA-positive, metastatic castrate resistant…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer
- Trial name
- NCT05570994
- Testing
- 177Lu HTK03170, 68Ga-HTK03149
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
This clinical trial will evaluate the safety and efficacy of [161Tb]Tb -PSMA-I\&T in men with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- VIOLET (NCT05521412)
- Testing
- [ 161 Tb]Tb PSMA I&T
- Where
- Australia
- Volunteers
- 66 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer, Metastatic Prostate Cancer
Clinically Actionable Tumor-Associated Antigens in Prostate Cancer
The goal of this observational study is to evaluate and validate the expression and prognostic value of 15 ADC-targetable membrane proteins (PSMA, B7-H3, STEAP1, TROP2, KLK2, HER2, TF, HER3, DLL3, SEZ6, STEAP2, MUC1, NECTIN4…
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Cancer (mCRPC)
- Trial name
- NCT07597369
- Testing
- Immunohistochemistry (IHC) Staining and Analysis
- Where
- China
- Volunteers
- 1,600 people
- Sponsor
- Peking University First Hospital
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- AtezoCab (NCT05168618)
- Testing
- Atezolizumab, Cabozantinib S-malate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Utah
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy…
- Conditions
- Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
- Trial name
- NCT04104776
- Testing
- Tulmimetostat, Enzalutamide
- Where
- 80 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castration-Resistant Prostate Carcinoma
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
- Trial name
- NCT07096999
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT07493512
- Testing
- Xaluritamig
- Where
- 14 sites in United States, Australia
- Volunteers
- 40 people
- Sponsor
- Amgen
Prostate Cancer
Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients
In this study it is aimed to analyze the efficacy and safety of Tb-161 PSMA I\&T in the 7.4 GBq activity in a large patient group of Lu-177 PSMA naïve mCRPC patients.
- Trial name
- TeLuNa (NCT07441837)
- Testing
- Terbium 161- PSMA I&T
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Ankara University
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as…
- Trial name
- NCT07226986
- Testing
- AMO959, AAA617, Enzalutamide
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer (mCRPC)
PROLONG (PRostateOLaparibONcombinationGcc) Study
The study will generate regionally relevant data to inform clinical practice, support treatment guidelines, and potentially contribute to supportive evidence for health authority discussions or scientific publications.
- Trial name
- PROLONG (NCT07674121)
- Testing
- Olaparib and Abiraterone Combination
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Metastatic Castration-resistant Prostate Cancer
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
This observational study aims to learn about the effects and safety of organoid-based drug sensitivity screening in mCRPC patients with bone metastases that progressed after first-line treatment.
- Trial name
- NCT06529549
- Testing
- Organoid-Based Drug Sensitivity Screening
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Prostate Cancer
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast…
- Trial name
- NCT07441889
- Testing
- HER2 FPBMC
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Virginia
Metastatic Castration-resistant Prostate Cancer
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled.
- Trial name
- PRESERVE-006 (NCT05682443)
- Testing
- ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
- Where
- 23 sites in United States
- Volunteers
- 148 people
- Sponsor
- OncoC4, Inc.
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either…
- Trial name
- MEVPRO-1 (NCT06551324)
- Testing
- PF-06821497, Docetaxel, Enzalutamide
- Where
- 224 sites in United States, Argentina and 21 more
- Volunteers
- 609 people
- Sponsor
- Pfizer
mCRPC, Male Urogenital Diseases
The Radium-select Study
Radium-223 is an established radionuclide therapy for patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastasis.
- Trial name
- NCT06659926
- Testing
- 68Ga-PSMA-PET/CT scan
- Where
- 5 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- The Netherlands Cancer Institute
mCRPC
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
- Trial name
- TALAPRO-2 (NCT03395197)
- Testing
- Talazoparib with enzalutamide
- Where
- 370 sites in United States, Argentina and 24 more
- Volunteers
- 1,054 people
- Sponsor
- Pfizer